Despite Diplomatic Tensions, Taiwan's Pharmaceutical Market Value Will Hit $8.4 Billion by 2020

Despite Diplomatic Tensions, Taiwan's Pharmaceutical Market Value Will Hit $8.4 Billion by 2020, says GlobalData

LONDON, UK (GlobalData), 15 July 2015 - Taiwan's pharmaceutical market will expand in value from $5.4 billion in 2013 to reach approximately $8.4 billion by 2020, despite the ongoing political tensions with China presenting an obstacle to economic development, says research and consulting firm GlobalData.

The company's latest report* states that diplomatic isolation, high out-of-pocket expenditure and the inefficient distribution of healthcare facilities are the foremost challenges to Taiwan's pharmaceutical sector.

According to Joshua Owide, GlobalData's Director of Healthcare Industry Dynamics, the diplomatic situation with China came further under the spotlight following the results of local elections in November 2014.

Owide explains: "The trade agreement with China in June 2013 has had a negative effect on President Ma Ying-Jeou's popularity, as many people in Taiwan fear it is a step towards reunification with China, and some believe that the free trade pacts will destroy local small businesses.

"The November 2014 local elections saw the ruling Nationalist Party, Kuomintang, win just six of the 22 contested seats, which many commentators attributed to its pro-China policies. With a general election scheduled for January 2016, the result could further impact trade opportunities for a country that only has formal diplomatic ties with 24 countries in Pacific, Latin American and African states."

Despite these reservations, Taiwan's pharmaceutical outlook remains positive, with opportunities presented by a free trade agreement with the US, low-taxation investment environment, harmonized clinical trial process, an efficient patent system, and strong incentives for Research and Development (R&D).

Owide continues: "Taiwan has signed a free trade agreement with the US, which is expected to positively impact the market, while government incentives, such as low taxation, make Taiwan a lucrative place for foreign investment.

"Biotechnology and pharmaceutical companies receive deductions from income tax liability for undertaking R&D into new drugs and high-risk medical devices, among other tax incentives, further boosting market growth."

*CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Republic of China (Taiwan)

-ENDS-

-NOTES TO EDITORS-

This report provides information on the healthcare landscape in Taiwan, including an overview of the pharmaceutical and medical device markets, a review of the reimbursement and regulatory landscape and an evaluation of the opportunities for and challenges to Taiwanese healthcare market growth.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData's team of industry experts.

For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx

-ABOUT GLOBALDATA-

GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For more information, please contact our Press Office on +44 (0)1204 543 537 or at [email protected]

Gain access to our latest press releases and expert analysis on developments in your industry. Subscribe to our RSS feed for the Pharmaceuticals industry, follow our LinkedIn Pharma Showcase Page, or connect with us on:

Facebook | LinkedIn | Twitter
 

Suggested Articles

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.